Why Quest Diagnostics Incorporated (DGX) Stock Rose 8.6% on Jul 23, 2026
What happened
Quest Diagnostics reported stronger-than-expected Q2 results with adjusted EPS of $3.12 (beating consensus of ~$2.82) and revenue of ~$3.04 billion, while raising full-year adjusted EPS guidance to $11.05–$11.25 from $10.63–$10.83 (per web synthesis corroborated by earnings filing). DGX surged +8.29% to $227.24 on elevated volume of 2.91M shares (3.44x average for this session time).
Monitor for analyst upgrades to price targets and any management commentary on margin trajectory and cost pressures in the diagnostic testing market during the earnings call (if held today or scheduled for later in the week).
Other developments that session
Quest Diagnostics Incorporated (DGX) reported EPS of $3.12 vs. $2.82 consensus estimate for Q2 FY2026, beating consensus by 10.6%.
Quest Diagnostics Incorporated (DGX) filed a new 8-K on July 23, 2026.
Frequently asked questions
Why did Quest Diagnostics Incorporated (DGX) stock rise on Jul 23, 2026?
Quest Diagnostics reported stronger-than-expected Q2 results with adjusted EPS of $3.12 (beating consensus of ~$2.82) and revenue of ~$3.04 billion, while raising full-year adjusted EPS guidance to $11.05–$11.25 from $10.63–$10.83 (per web synthesis corroborated by earnings filing). DGX surged +8.29% to $227.24 on elevated volume of 2.91M shares (3.44x average for this session time).
How much did DGX stock rise on Jul 23, 2026?
DGX rose 8.6% during the Jul 23, 2026 trading session.